136 related articles for article (PubMed ID: 36534632)
1. Protein CD133 as a tumor stem cell marker.
Grabovenko FI; Kisil OV; Pavlova GV; Zvereva ME
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(6):113-120. PubMed ID: 36534632
[TBL] [Abstract][Full Text] [Related]
2. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
[TBL] [Abstract][Full Text] [Related]
3. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
Bidlingmaier S; Zhu X; Liu B
J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
[TBL] [Abstract][Full Text] [Related]
4. The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels.
Koyama-Nasu R; Takahashi R; Yanagida S; Nasu-Nishimura Y; Oyama M; Kozuka-Hata H; Haruta R; Manabe E; Hoshino-Okubo A; Omi H; Yanaihara N; Okamoto A; Tanaka T; Akiyama T
PLoS One; 2013; 8(1):e53710. PubMed ID: 23326490
[TBL] [Abstract][Full Text] [Related]
5. Limits of CD133 as a marker of glioma self-renewing cells.
Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
[TBL] [Abstract][Full Text] [Related]
6. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
7. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.
Ogden AT; Waziri AE; Lochhead RA; Fusco D; Lopez K; Ellis JA; Kang J; Assanah M; McKhann GM; Sisti MB; McCormick PC; Canoll P; Bruce JN
Neurosurgery; 2008 Feb; 62(2):505-14; discussion 514-5. PubMed ID: 18382330
[TBL] [Abstract][Full Text] [Related]
8. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
9. CD133: molecule of the moment.
Mizrak D; Brittan M; Alison M
J Pathol; 2008 Jan; 214(1):3-9. PubMed ID: 18067118
[TBL] [Abstract][Full Text] [Related]
10. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.
Grosse-Gehling P; Fargeas CA; Dittfeld C; Garbe Y; Alison MR; Corbeil D; Kunz-Schughart LA
J Pathol; 2013 Feb; 229(3):355-78. PubMed ID: 22899341
[TBL] [Abstract][Full Text] [Related]
11. CD133: holy of grail of neuro-oncology or promiscuous red-herring?
Donovan LK; Pilkington GJ
Cell Prolif; 2012 Dec; 45(6):527-37. PubMed ID: 23106300
[TBL] [Abstract][Full Text] [Related]
12. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells.
Yao J; Zhang T; Ren J; Yu M; Wu G
Oncol Rep; 2009 Oct; 22(4):781-7. PubMed ID: 19724856
[TBL] [Abstract][Full Text] [Related]
13. CD133 is a marker of bioenergetic stress in human glioma.
Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
[TBL] [Abstract][Full Text] [Related]
14. [Chemoresistance of CD133(+) tumor stem cells from human brain glioma].
Bi CL; Fang JS; Chen FH; Wang YJ; Wu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):568-73. PubMed ID: 17767043
[TBL] [Abstract][Full Text] [Related]
15. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
Bao S; Wu Q; McLendon RE; Hao Y; Shi Q; Hjelmeland AB; Dewhirst MW; Bigner DD; Rich JN
Nature; 2006 Dec; 444(7120):756-60. PubMed ID: 17051156
[TBL] [Abstract][Full Text] [Related]
16. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CD133 promotes drug resistance in C6 glioma cells.
Angelastro JM; Lamé MW
Mol Cancer Res; 2010 Aug; 8(8):1105-15. PubMed ID: 20663862
[TBL] [Abstract][Full Text] [Related]
18. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
19. CD133 as a marker for cancer stem cells: progresses and concerns.
Wu Y; Wu PY
Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
